Joe Flisak
About Joe Flisak
Joe Flisak serves as the CMC API Manufacturing Lead at Venatorx Pharmaceuticals, Inc., where he oversees small molecule development and the supply of clinical trial materials. He has extensive experience in the pharmaceutical industry, having held various leadership roles at GSK US over several decades.
Current Role at Venatorx Pharmaceuticals
Joe Flisak serves as the CMC API Manufacturing Lead at Venatorx Pharmaceuticals, Inc. since 2020. In this role, he provides strategic oversight and leadership for small molecules development activities, focusing on process chemistry and route development. He is responsible for overseeing the manufacture and supply of clinical trial materials and authors CMC regulatory documents. Flisak manages a departmental staff of approximately 50 scientists, ensuring effective collaboration and productivity within the team.
Previous Experience at GSK US
Prior to his current position, Joe Flisak held various roles at GSK US over a span of more than two decades. His positions included Senior Investigator, Synthetic Chemistry from 1986 to 1989, Assistant Director, Synthetic Chemistry from 1990 to 1993, Associate Director, Synthetic Chemistry from 1993 to 2000, Director, Synthetic Chemistry from 2000 to 2010, Director, API Chemistry from 2013 to 2014, and Senior Director, API Chemistry from 2014 to 2019. His extensive experience at GSK US involved leadership in synthetic chemistry and API development.
Educational Background
Joe Flisak holds a Doctor of Philosophy (Ph.D.) in Organic Chemistry from Rutgers University. He also completed post-doctoral studies in A.I. Meyers/Organic Synthesis at Colorado State University. Earlier in his academic journey, he earned a Bachelor of Science (B.S.) in Chemistry from the University of Scranton. His educational background provides a strong foundation for his expertise in the pharmaceutical industry.
Leadership and Recruitment
In his current role at Venatorx Pharmaceuticals, Joe Flisak is responsible for the recruitment of new scientists in his department. His leadership encompasses not only strategic oversight of projects but also the development of talent within the organization. This focus on building a skilled team supports the company's objectives in drug development and clinical trials.